Inoue et al. reported that Noxa mediated HDAC (histone deacetylase) inhibitor-induced apoptosis and suggested that activated Noxa could be a potential clinical target for chronic lymphocytic leukemia and lymphoma therapy (Inoue et al., 2007). This evidence concerns the gene PMAIP1 and B-cell chronic lymphocytic leukemia.